3月 2026Humacyte的市場佔有率分析

Humacyte Global, Inc. (“Humacyte” or “we”) recognize the importance of protecting the privacy of your personal information, and we have prepared this Privacy Policy to provide you with important information about our privacy practices. This Privacy Policy applies when you use any website, application, or other online service that links to or refers to this … Continued

健康 > 生物技術和製藥

域名humacyte.com

成立年份2004

僱員51 - 200

年度營收$1M - $2M

Humacyte

Humacyte（包含公司地區）

humacyte.com

查看更多網站流量與參與度資訊

Humacyte截至 3月 2026 的總收入為 1M - 2M

Humacyte 熱門網域產生的總收入

Humacyte 熱門網域 3 年內的總收入

Humacyte 熱門網域的總收入

humacyte.com1M - 2M

透過銷售情報查看更多內容

Humacyte的熱門網域總造訪量

了解Humacyte市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

humacyte.com11.6K

透過銷售情報查看更多內容

Humacyte的熱門網域平均造訪時長

分析Humacyte參與度指標。

過去 3 個月平均造訪時長

子公司細目

humacyte.com00:00:05

透過銷售情報查看更多內容

Humacyte的熱門網域平均頁面瀏覽量

了解Humacyte如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

humacyte.com1.42

透過銷售情報查看更多內容

Humacyte按網域劃分的熱門競爭對手

3月 2026的熱門類似網站，依相似度排名

aviditybiosciences.com公司名Avidity Biosciences僱員51 - 200總部美國, 加利福尼亞, San Diego年度營收$15M - $25M訪問總量16.6K健康 > 生物技術和製藥

使用的熱門技術Humacyte

这些是Humacyte顶级域名使用的行业网站技术

電子商務 (4)

Swap

小工具 (4)

Twemoji

付費廣告 (3)

DoubleClick

轉換與分析 (3)

Google Analytics

更多技術

10

檢視所有

新聞與訊號來自Humacyte

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Humacyte, Inc. is developing disruptive biotechnology platform.Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine.

新聞Humacyte, Inc. had issues with inadequate "quality oversight." on Oct 17th '24.Then, on October 17, 2024, the FDA issued a Form 483 concerning Humacyte's Durham, North Carolina facility, which revealed a number of violations, including "no microbial quality assurance," "no microbial testing," and inadequate "quality oversight."

新聞Humacyte, Inc. is developing biotechnology platform.Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine.